Press releases

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...

A second cosmetic active ingredient will be developed as part of the collaboration between DEINOVE and Hallstar-Oléos. The Occitanie Region...

The General Meeting approved the contribution in kind of the BIOVERTIS (parent company of MORPHOCHEM) shares and options and the issuance...

The selected producer strain shows performance comparable to petrochemical products on the market today. The tests continue to validate the...

HEBELYS ® is a natural active ingredient produced by the fermentation of Sphingomonas , a bacterium belonging to the DEINOVE proprietary...

MORPHOCHEM's MCB3837 antibiotic compound aims to treat severe gastrointestinal infections caused by Clostridium difficile , a priority...

Deinove scientific platform has designed an exclusive Deinococcus fermentation process to deliver the first pure Phytoene for application...

Acceleration of the Antibiotics program: €14.6m of funding by Bpifrance (including € 10.4m for the DEINOVE Group) and structuring of the...

The program developed by REDX PHARMA focuses on a new class of antibiotics aimed at treating the most lethal infections (caused by...

DEINOVE expands the AGIR project’s field of investigation for the discovery of novel antibiotic structures by accessing the strain bank of...